Akero’s cash, cash equivalents and short and long-term marketable securities as of June 30, 2025, were $1,086.2 million. Akero believes that its cash, cash equivalents and short and long-term marketable securities will be sufficient to fund its current operating plan into 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics releases ‘What This Means’ segment for investors
- Akari Therapeutics reiterates commitment to research on PH1
- Akari Therapeutics ‘just getting started,’ initiated with a Buy at Maxim
- Akari Therapeutics initiated with a Buy at Maxim
- Akari Therapeutics Shareholders Approve Key AGM Resolutions